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ABSTRACT 
CREATING AN INTERNET-BASED DATABASE 
OF 
BETA THALASSEMIA MUTATIONS 
by Shalu Susan George 
Beta thalassemia, one of the most common single-gene disorders world-wide, is 
caused by some 200 mutations in the beta globin gene. The disease, in its most severe 
form, can result in a chronic anemia which can only be treated with repeated blood 
transfusions. In order to inform and educate students, patients, the general public, and 
possibly the medical community, about this incurable but preventable disease, an 
internet-based database was created containing information regarding various mutations 
that result in beta thalassemia. MySQL was used to create the database back-end, while 
PHP, JavaScript, and Dreamweaver were used to make the front-end. The database 
currently contains 106 mutations, drawn from 139 literature references. The user-
friendly database also provides the entire sequence of the beta globin gene, in a clickable-
map format, as well as the ability to generate filtered mutation lists. Many future 
improvements have been planned for this database. 
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Chapter 1 Introduction 
The thalassemias, including alpha and beta thalassemia, are the most common 
monogenic diseases in humans. Thalassemia was first recognized as a disorder by 
researchers in the United States and Italy, in 1925 (Weatherall, 2004). The name of the 
disease was coined by George Whipple and is derived from the Greek words meaning 
"sea" and "blood" due to the mistaken notion that the disease was restricted to individuals 
of Mediterranean origin (Weatherall, 2004). Over the years, however, it became apparent 
that the disease was equally, if not more prevalent, in many parts of the world. 
1.1 The Thalassemias 
The thalassemias are disorders of hemoglobin. Hemoglobin is the major protein 
found in red blood cells and is responsible for binding and carrying oxygen from the 
lungs to the various body tissues. Each hemoglobin molecule is a tetramer, made up of 
two alpha-like globin chains and two beta-like globin chains. Each globin chain has a 
heme group attached (Weatherall, 2004). Oxygen is bound and transported through the 
heme-groups. 
A heme group is a prosthetic group, that is, it is a non-protein group bound to a 
protein. The heme group consists of an iron atom contained in the center of a large 
heterocyclic organic ring called a porphyrin (Casiday & Frey, 1998). The heme group is 
bound to a histidine residue in the globin protein. Both the heme group and the 
hemoglobin protein undergo conformational changes upon the binding and unbinding of 
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oxygen. These changes in shape improve the efficiency of the hemoglobin molecule, 
enabling it to bind or release more oxygen (Casiday & Frey, 1998) 
Abnormalities in hemoglobin, resulting from the deficiency or complete absence 
of one or more of the globin chains, give rise to the thalassemias. Patients with 
thalassemia suffer from varying degrees of anemia, that is, a shortage of red blood cells 
(Weatherall & Clegg, 2001). 
1.2 Beta Thalassemia 
One major type of thalassemia is beta thalassemia, which results from a disorder 
in the production of beta globin. In the fetus, the primary beta-like globin is gamma-
globin; however, soon after birth, a switch in globins takes place such that beta globin 
replaces gamma-globin (Weatherall, 2004). The major adult hemoglobin, called HbA, 
thus contains alpha globin and beta globin. The symptoms of beta thalassemia become 
apparent in a patient, only a few months following birth, when the switch to adult 
hemoglobin occurs (Weatherall, 2004). 
Beta thalassemia poses the greatest burden on health care, compared to the other 
thalassemias, where the most severe forms of the disease often lead to death in-utero. 
Beta thalassemia symptoms develop within the first two years of birth and without 
treatment a patient, with the most severe form of the disease, would die by 20 years of 
age. The clinical description of beta thalassemia was first published in the US by two 
Detroit based physicians - Thomas B. Cooley and Pearl Lee. As a result, beta 
thalassemia is often also referred to as Cooley's anemia (Weatherall, 2004). 
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1.3 Genetic Cause of Beta Thalassemia 
Beta thalassemia is caused by mutations in the beta globin gene. The gene is part 
of the beta globin locus, located on chromosome 11, in humans (Nienhuis, Anagnou, & 
Ley, 1984). Mutations in the gene result in either a deficiency of beta globin, referred to 
as beta+ thalassemia, or a complete lack of beta globin, referred to as betaO thalassemia 
(Weatherall, 2004). The disease is an autosomal recessive disease, meaning that 
individuals that have the most severe form of the disorder carry two mutations - one in 
their paternal gene and one in their maternal gene. The disorder varies in severity. 
Individuals with beta thalassemia minor carry a mutation in only one of their two genes 
and have little to no symptoms. Those with beta thalassemia intermedia carry a mutation 
in either one or both of their genes and have moderate symptoms. Patients with beta 
thalassemia major have a mutation in both their genes and are the worst affected, 
requiring blood transfusions every 8-12 weeks or more frequently (Weatherall, 2004). 
Some 200 different mutations give rise to beta thalassemia. Most thalassemia major 
patients are compound heterozygotes and carry a different mutation in each gene 
(Weatherall, 2004). 
1.4 The Link between Beta Thalassemia and Malaria 
J. B. S. Haldane, in 1945, was the first one to suggest a connection between the 
high frequencies of thalassemia, seen in some parts of the world, and the prevalence of 
malaria in these regions. He believed that individuals that were heterozygous for globin 
mutations were somehow protected against a deadly case of malaria. This idea came to 
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be known as the Haldane hypothesis. The mechanism of this protection, in the case of 
thalassemia, is not clear (Kwiatkowski, 2005). Protection has been attributed to the 
inability of the parasite to invade or grow in the distorted red blood cells or the inability 
of the parasite to complete its lifecycle due to premature destruction of the mutant red 
blood cells (Ayi, Turrini, Piga, & Arese, 2004). Malaria, a deadly killer responsible for 
millions of deaths annually, has acted as one of the strongest evolutionary forces for the 
selection and maintenance of protective globin mutations in human populations 
(Kwiatkowski, 2005). 
1.5 Distribution of Beta Thalassemia 
Beta thalassemia has been prevalent in many parts of the Old World, especially in 
the so called malaria belt. The disease is prevalent, not only in the regions surrounding 
the Mediterranean, but also in Africa, the Middle East, the Indian subcontinent, South-
east Asia, and Southern China (Vichinsky, MacKlin, Waye, Lorey, & Olivieri, 2005; 
Weatherall, 2004). A few mutations dominate in each region while the rest of the 
mutations are not so commonly seen (Weatherall, 2004). 
Beta thalassemia was brought to the New World by immigrants from the 
Mediterranean region, Africa, and, more recently, Asia (Vichinsky et al., 2005). 
1.6 Phenotype of Beta Thalassemia 
Beta thalassemia affects multiple organs but the primary phenotype of the 
disorder is hemolytic anemia (Cunningham, Macklin, Neufeld, & Cohen, 2004). Each 
red blood cell contains millions of hemoglobin molecules. Beta thalassemia patients, due 
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to their deficiency of beta globin, have abnormal hemoglobin, and, as a result, their red 
blood cells are microcytic, that is, they are smaller than normal and they have lower 
hemoglobin content. These mutated red blood cells are recognized as defective by the 
spleen, and are destroyed prematurely (Cunningham et al., 2004). The premature 
destruction of red blood cells leads to a severe case of anemia. 
The spleen, in the process of destroying large numbers of red blood cells, 
becomes hyperactive and enlarged, a condition referred to as splenomegaly (Cunningham 
et al., 2004; Weatherall & Clegg, 1996). The iron, from the destroyed red blood cells, is 
normally stored in the liver and spleen, so that it can be used later on to make new cells. 
However, in patients, the rapid destruction of high numbers of red blood cells leads to an 
iron overload in the liver and spleen, as well as in many other organs, leading to organ 
failure. Patients often suffer from hepatitis or liver carcinoma. Iron overload in the 
ovaries, testes, and hypothalamus leads to infertility, in the pancreas it leads to diabetes, 
in the gall bladder it leads to gall stones, while in the heart it leads to irregular heart-beat 
and heart failure (Cunningham et al., 2004). 
The hyperactive spleen not only destroys red blood cells, but also some white 
blood cells, which in turn causes immunosuppression (Cunningham et al., 2004). The 
bone marrow, which is the site of red blood cell production, also expands, to keep up 
with the large requirement of new cells, needed to replace the destroyed ones. This 
expansion of the bone marrow causes the bones to become fragile and results in an 
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enlargement of the skull and facial deformities in untreated children (Cunningham et al., 
2004; Weatherall & Clegg, 1996). 
1.7 Treatment for Beta Thalassemia 
There are no cures for beta thalassemia and the disease can only be managed 
through frequent blood transfusions, iron chelation therapy, and splenectomy (surgical 
removal) in case of an enlarged spleen (Cunningham et al., 2004). Chronic cases are 
treated with monthly transfusions of "washed, filtered, or frozen red cells" (Marengo-
Rowe, 2007). Most of the mortality associated with beta thalassemia results from iron-
overload and hence all long-term transfusion programs are accompanied by treatment 
with an iron-chelating agent. The most widely used iron-chelator is deferoxamine 
(Cunningham et al., 2004; Marengo-Rowe, 2007). As it is poorly absorbed from the 
gastrointestinal tract, it has to be administered intravenously or subcutaneously, through a 
metering pump, 4-5 times a week, and for a period of 8 hrs (Marengo-Rowe, 2007). 
Alternative therapies that are being considered include reactivation of fetal 
hemoglobin, bone marrow transplantation, and somatic gene therapy (Marengo-Rowe, 
2007). The levels of fetal hemoglobin (HbF) generally drop soon after birth. However, it 
has been found that continuing to maintain high levels, using various therapeutic agents 
like erythropoietin, hydroxyurea, and cytarabine, can decrease the frequency of 
transfusions. HbF reactivation therapy only works for some patients (Marengo-Rowe, 
2007). 
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Bone marrow transplantations from a human leukocyte antigen (HLA) matched 
donor have been performed for about a thousand patients in the US. This therapy works 
only for children and has many associated risks (Marengo-Rowe, 2007; Weatherall, 
2004). Gene therapy to treat beta thalassemia has not been very successful as it is difficult 
to achieve the fine-tuned balance between alpha and globin chain production seen in 
normal cells (Marengo-Rowe, 2007). 
1.8 Diagnosis and Prevention of Beta Thalassemia 
As beta thalassemia requires life-long management, it puts a great deal of pressure 
on patients and the public health system. Prevention, through carrier screening and 
prenatal diagnosis, thus becomes vitally important. Primary screening involves various 
hematological tests, such as measurements of mean corpuscular volume (MCV), which is 
a measure of the size of a red blood cell, and mean corpuscular hemoglobin (MCH), 
which is a measure of the hemoglobin content of a red blood cell (Old, 2003). High 
Pressure Liquid Chromatography (HPLC) is used to look at the hemoglobin profile 
(Bhardwaj, Zhang, Lorey, McCabe, & McCabe, 2005; Lorey, 2000; Old, 2003). Patients 
with beta thalassemia have elevated levels of HbA2 (the secondary adult hemoglobin) 
and HbF (fetal hemoglobin) (Old, 2003). 
If a patient is found to be a carrier, further testing is carried out to identify the 
mutation. Tests such as reverse dot blot or various PCR based methods are used to test 
for specific mutations (Bhardwaj et al., 2005; Old, 2003). 90% of the mutations can 
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usually be identified in this manner. For the remaining 10%, rare mutations, the entire 
beta globin gene is sequenced (Old, 2003). 
When both parents are carriers, they have a 25% probability of having a 
thalassemia major child. In such cases, prenatal diagnosis is highly recommended. 
Amniocentesis or chorionic villus sampling (CVS) is commonly used for this purpose 
(Marengo-Rowe, 2007; Old, 2003). Amniocentesis involves using a needle to withdraw 
amniotic fluid, which contains the cells of the fetus. These cells can then be tested to 
determine the fetus's genotype. Alternatively, CVS can be carried out earlier in the 
pregnancy. CVS involves inserting a catheter through the cervix and withdrawing a piece 
of tissue from the outer layer of the embryo sac. This tissue has the same genotype as the 
fetus. If the fetus is found to have beta thalassemia major, the parents can opt to 
terminate the pregnancy. 
In order to avoid the trauma of pregnancy termination, parents can also opt for an 
expensive procedure called pre-implantation diagnosis. In this procedure a number of 
embryos are prepared in-vitro from which a healthy embryo is then chosen and implanted 
(Marengo-Rowe, 2007). 
1.9 Purpose of the Database 
The beta thalassemia database, created as part of this project, will help increase 
awareness about the disease amongst the general public. The database could also be used 
as a teaching and learning tool in academic settings as well as in hospitals to educate 
patients and those in the allied medical professions. 
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The disease database could be utilized as an awareness tool as it contains 
information about the causative mutations and the affected populations. In the future, the 
database will include disease related information and links, as well as the basics of 
genetics and hematology. Thus, users will not only learn about the disease, but also will 
become aware of whether they belong to a high-risk community. 
In the United States (US), thalassemia was previously considered as a disease 
only afflicting Mediterranean immigrants. Since the 1980's, however, the US has seen a 
sharp increase in immigration from various Southeast Asian countries where beta 
thalassemia is found at a higher frequency (Vichinsky et al., 2005; Lorey, 2000). As a 
result, beta thalassemia is rapidly emerging as "a new minority disease" in this country 
(Vichinsky et al., 2005). As beta thalassemia has no cure, management of the disease 
involves providing monthly blood transfusions to an ever growing number of patients; 
this in turn increases the pressure on blood banks and burdens the health care system. 
Under these circumstances, spreading awareness about the disease and promoting 
prevention, through carrier screening and prenatal diagnosis programs, becomes 
imperative. The database will contribute towards this effort in the US where knowledge 
of the disease has been found to be poor, even in highly susceptible communities 
(Armeli, Robbins, & Eunpu, 2005). 
The only database for the hemoglobinopathies currently available to medical 
professionals, patients, researchers, and students alike, is called HbVar (described in 
detail in Chapter 2 Section 2.1), based at Penn State University (Patrinos, Giardine, 
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Riemer, Miller, & Chui, 2004). This database includes all globin mutations rather than 
just beta thalassemia mutations. The database is not very user-friendly, especially for 
non-professionals, and assumes considerable background knowledge of the disease and 
its genetics. Also, no web site or database on the internet, including HbVar, currently 
contains the entire sequence of the beta globin gene. The beta thalassemia database, 
created as part of this project, overcomes these deficiencies. The database not only 
provides the entire beta globin gene sequence, in an easy-to-follow format, but also is 
intuitive to use and hence can be easily utilized as a learning tool. 
The database could also be employed as a teaching aid in courses of genetics, 
bioinformatics, and hematology. The database provides many tools to allow students to 
learn more about beta thalassemia, its distribution, and the mutations that give rise to it. 
The references provided for each mutation, with links to the article abstracts, give users 
an opportunity to further explore the disease and its many interesting variations. Since 
the beta globin gene is a fairly small gene, and is not alternatively spliced, it is ideal for 
studying genetic concepts like transcription, splicing, and translation. The size of the 
gene also makes it easier to understand gene structure. Since beta thalassemia involves 
some 200 mutations, including insertions, deletions, and substitutions, the database could 
educate students about the different types of mutations and their consequences. Students 
also have the option of learning the effect of a base insertion, deletion, or substitution by 
manipulating the beta globin sequence provided by the web site. 
10 
Finally, the database could be utilized in a hospital setting, to educate nurses and 
those in the allied medical fields. It could also be used by genetics counselors to help 
patients and their families better understand the disease. 
The following chapters describe the process involved in the creation of the 
database as well as the database content. Chapter 2 deals with the design and 
implementation of the database back-end. Chapter 3 provides the details of the various 
web pages that make up the database front-end. Chapter 4 gives an overview of the 
records in the database. Finally, some ideas for future improvements of the database are 
presented in Chapter 5. 
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Chapter 2 Creation of the Database Back-end 
The back-end is that portion of software that is not directly accessible to an end-
user. It generally includes the Database Management System (DBMS) which is used to 
organize and store data. 
The creation of the database back-end involved identifying the data sources, 
collecting mutation-related data from the sources, installing the software needed for 
database creation, creating and implementing the database design, and, finally, populating 
the created database with the gathered data. 
2.1 Data Sources 
The mutations for the database were gathered from three sources (a) HbVar, an 
online database of hemoglobin variants and thalassemia mutations (Wajcman, Patrinos, & 
Anagnou, 2008), (b) The Thalassaemia Syndromes, the book by Weatherall and Clegg 
(2001), and (c) PubMed, an online database of citations and abstracts of biomedical 
research articles ("NCBI: PubMed," 2008). 
The HbVar Database. The HbVar database is a "publicly available database" based at 
Perm State University, PA, USA (Patrinos et al., 2004) and was created through an 
association between Perm State University, INSERM Creteil, France and Boston 
University Medical Center, MA, USA (Wajcman et al., 2008). The initial data for HbVar 
was drawn from the books A Syllabus of Human Hemoglobin Variants (Huisman, Carver, 
& Efremov, 1998) and A Syllabus of Thalassemia Mutations (Huisman, Carver, & Baysal, 
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1997). The database is maintained and updated with new mutations by three curators -
Dr. Henri Wajcman, Dr. George Patrinos, and Dr. Nick Anagnou (2008). 
The database claims to provide the most current information on different types of 
mutations that result in thalassemia (Wajcman et al., 2008). The information provided 
for a mutation includes sequence changes, the hematological and pathological effects of 
the mutation, the population-wise distribution of the mutation, and list of references 
(Patrinos et al., 2004). The database is primarily aimed at researchers and those in the 
medical community. 
The HbVar database served as one of the sources for mutations and their 
references. The mutation description was taken from HbVar and each of the cited 
references was referred to for further information about the mutation. The information 
obtained from the references was then cross-checked with what had been recorded by 
HbVar. 
"The thalassaemia syndromes" by Weatherall and Clegg (2001). Sir David J. 
Weatherall, the primary author of the book The thalassaemia syndromes, is a 
distinguished and multi-award-winning geneticist who has made outstanding 
contributions to the field of thalassemia research (Kan, 2004). He published his first 
paper on thalassemia as early as 1960 and spent nearly 40 years pioneering countless 
discoveries and authoring as many as 14 books and 600 papers on the subject (Kan, 
2004). His above mentioned book, which is currently in its 4 edition, is unarguably 
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regarded as "the Bible" of thalassemia and is a "must read" for anyone in this line of 
research (Kan, 2004). 
Dr. Weatherall's book was used as an added data source. Additional mutations, 
not included in the HbVar database, were obtained from the book. For mutations 
common to both the book and HbVar, extra references, cited in the book but not in 
HbVar, were noted. 
The PubMed Database. PubMed, a database maintained by the National Library of 
Medicine, is a collection of over 16 million abstracts and citations of articles from almost 
every well known biomedical journal ("NCBI: PubMed," 2008). The article citations also 
include a link to the full-text article. 
The PubMed database was used to access the reference articles for each mutation. 
In addition, the database was used to search for articles reporting any newly discovered 
mutations. A few new mutations were found in articles published in late 2007 and early 
2008. 
Some mutation entries in the HbVar database are based on personal 
communications, from researchers, received by the curators of HbVar. Some of these 
researchers, at a later date, publish a journal article based on the same findings. 
However, the HbVar entries are not updated with the journal citations. Hence, in cases 
where citations were absent, the PubMed database was searched for such a possible 
article by the researcher. 
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2.2 Data Collection 
The gathered information for each mutation was initially recorded in a paper-
based form. The mutation description and disease type (betaO, beta+) were noted from 
the data source. The mutation type (substitution, insertion or deletion) was derived from 
the mutation description. The starting position of the mutation, the mutation length, and 
the mutation location were deduced from the sequence of the beta globin gene. The 
effect of the mutation was either obtained from the references or was inferred on the basis 
of basic genetic principles. The disease severity (thalassemia major, intermedia or 
minor), the disease distribution (by nationality and ethnicity), and frequency of 
occurrence (common, rare, novel) were drawn from the references. Additional 
noteworthy facts, found in the references, were recorded as comments. The reference 
citations and PubMed identification numbers (PMIDs) were taken from the PubMed 
database. 
2.3 Software Used for Database Back-end 
Virtual Machine - Vmware. In order to create the back-end, a virtual machine was first 
setup using VMware. VMware is software that aids in the creation of an abstract 
machine within a machine ("VMware: Virtualization Basics," 2008). It creates the effect 
of having two separate, independent computers within a physical computer. The virtual 
machine is referred to as the guest system, while the physical computer is referred to as 
the host system ("VMware: Virtualization Basics," 2008). 
15 
A VMware virtual machine provides many advantages. It allows the use of 
multiple operating systems on the same computer ("VMware: Virtualization Basics," 
2008). It enables users to switch between operating systems without actually re-booting 
the computer. The virtual machine is also portable ("VMware: Virtualization Basics," 
2008). All the contents of the VMware virtual machine are stored in a single folder and 
hence can easily be moved or copied onto a different computer. The virtual machine can, 
in addition, acquire its own IP address and use it to communicate with the host system 
over a network ("VMware: Virtualization Basics," 2008). 
Since it was decided to create the database in a Linux operating system 
environment, a virtual machine was required to enable easy switching between the 
Windows XP and Linux operating systems. 
Operating System - CentOS 5. CentOS is a "Community ENTerprise Operating 
System," which means that it is a freely available, non-commercial software that is 
maintained and updated by a community of open source contributors ("CentOS: Home 
page"). CentOS is based on Red Hat Enterprise Linux which is a commercial product. 
The advantages of CentOS are that it is a robust and reliable operating system. It 
also comes with the latest versions of various server and application software, including 
MySQL 5.0. 
CentOS was chosen as the operating system because it was freely available and 
included the latest version of the database management system MySQL. CentOS also 
provided a stable development environment. 
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Database Management System - MySQL 5.0. MySQL, which stands for Structured 
Query Language, is a very popular, openly available, DBMS. MySQL is popularly used 
for web applications. It is used by many well known web sites such as YouTube, Flickr, 
Friendster, Wikipedia, Adobe, and Nokia. It can store large amounts of data, is flexible, 
and is fast at both storing and retrieving data ("Top reasons to use MySQL"). 
2.4 Designing the Database 
Database designing involves firstly, identifying the data to be stored in the 
database and secondly, choosing appropriate structures to represent and store the data. 
Database designing is the first step in creating a database and it is done before the actual 
database is created and populated with data. 
The description of a database is called the database schema. The schema is 
defined during the designing phase and is not expected to change frequently. Different 
types of database schemas, based on different sets of rules, can be made. For this 
database, an Entity-Relationship (ER) schema was created (shown in Figure 2.1). 
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Figure 2.1. The Entity-Relationship database schema. 
The ER schema is a popular high-level conceptual data model (Elmasri & 
Navathe, 2007). It views the database in terms of entities and relationships. Rectangular 
boxes are used to depict the entities. An entity is any real world object or a concept. 
Five entities were defined - MUTATION, DISTRIBUTION, REFRENCES, CURATOR, 
and USER_COMM (user comments). 
Double rectangular boxes stand for weak entities. A weak entity is one that 
cannot exist by itself and depends on another entity for its existence. In this case 
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DISTRIBUTION is a weak entity that depends on the entity MUTATION or, in other 
words, a distribution does not make sense till it is tied to a mutation. 
Ovals are used to represent the attributes of an entity. An attribute is a property 
that describes an entity. The attributes that are primary keys are underlined by a solid 
line (e.g., MutID, RefID). A primary key is an attribute that can be used to uniquely 
identify each instance of an entity. Weak entities do not have complete primary keys; 
instead they have partial keys. Partial keys are underlined by a broken line (e.g., 
Nationality, Ethnicity). The primary key of a weak entity is constructed by combining its 
partial key with the primary key of the related strong entity (also called the owner entity). 
In this case Nationality and Ethnicity need to be combined with MutID in order to 
construct a primary key for DISTRIBUTION. An attribute that can have multiple values 
is surrounded by a double oval. 
Diamonds are used to represent the relationships between the entities. A 
relationship is the association between two or more entities. Double diamonds are used 
to depict the relationships of weak entities. 
Lines connecting the diamonds to the boxes stand for the participation of an entity 
in a relationship. Partial participation is represented by a single line. A partial 
participation, for instance, is seen between the entity MUTATION and the relationship 
HAS, since a mutation may or may not have a user comment. Total participation, on the 
other hand, is represented by double lines. Total participation is seen between the entity 
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USER_COMM and the relationship HAS, as a user comment must have a mutation 
associated with it. 
Furthermore, the type of relationship is given alongside the lines. A relationship 
could be one-to-one (1:1), one-to-many (1:N) or many-to-many (M:N). The entities 
MUTATION and REFRENCES have a many-to-many relationship because one mutation 
can have multiple references and, at the same time, one reference can have multiple 
mutations associated with it. On the other hand, entities MUTATION and 
DISTRIBUTION have a one-to-many relationship because one mutation can have 
multiple populations associated with it. 
An ER schema is best suited for end users and helps them perceive data (Elmasri 
& Navathe, 2007). However, a schema that can be both understood by end users and, at 
the same time, can easily be implemented on a computer is the Relational schema. The 
ER schema can easily be mapped to a Relational schema. 
2.5 Implementing the Database Design 
A Relational schema was created to enable the implementation of the database 
design. An ER-to-Relational Mapping Algorithm from Elamsri and Navathe (2007, pp. 
224-30) was used. The Relational schema is shown in Figure 2.2. 
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The mapping steps used to create the schema are described below: 
Step 1: Mapping of Regular Entity Types. For each regular (strong) entity type in the 
ER schema, a relation was created that included all the attributes of the entity (a relation 
is synonymous to a table of the database). A primary key was also chosen for each 
relation. Thus, the relations MUTATION, REFRENCES, CURATOR, and 
USER_COMM were created. The primary key for each of these relations is depicted in 
bold in Figure 2.3. The primary key for MUTATION is MutID (mutation ID), for 
REFRENCES is RefID (reference ID), for CURATOR is Updn_dtime (updation date and 
time), and for USER_COMM is Entrydtime (entry date and time). 
Step 2: Mapping of Weak Entity Types. For each weak entity type in the ER schema, a 
relation was created that included all the attributes of the entity. In addition, the primary 
key of the owner entity was included as a foreign key attribute. Thus, the relation 
DISTRIBUTION was created and MutID, from the relation MUTATION, was included 
as a foreign key. The foreign key, MutID, is depicted as underlined in Figure 2.3. The 
source of the foreign key is indicated with an arrow. The primary key of 
DISTRIBUTION is a combination of the partial keys Nationality, Ethnicity, and the 
primary key of its owner MutID. 
Step 3: Mapping of Binary 1:1 Relationship Types. For each 1:1 relationship type in 
the ER schema, a corresponding relationship was established between the relations in the 
Relational schema. The primary key of one participant in a 1:1 relationship was included 
as a foreign key of the other participant. Thus, to map the 1:1 relationship between the 
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entities MUTATION and CURATOR, the primary key of the MUTATION relation was 
included as a foreign key in the CURATOR relation. The foreign key, MutID, is 
depicted as underlined in Figure 2.3. The source of the foreign key is indicated with an 
arrow. 
Step 4: Mapping of Binary 1:N Relationship Types. For each 1:N relationship type in 
the ER schema, a corresponding relationship was established between the relations in the 
Relational schema. The primary key of the participant on the l-side of the relationship 
was included as a foreign key of the participant on the N-side. Thus, to map the 1 :N 
relationship between the entities MUTATION and USER_COMM, the primary key of 
the MUTATION relation was included as a foreign key in the USER_COMM relation. 
The foreign key, MutID, is depicted as underlined in Figure 2.3. The source of the 
foreign key is indicated with an arrow. The 1:N relationship between the entities 
MUTATION and DISTRIBUTION was mapped in a similar manner. 
Step 5: Mapping of Binary M:N Relationship Types. For each M:N relationship type 
in the ER schema, a new relation was created to represent the relationship between the 
participating entities. The primary keys of the participating relations were included as 
attributes in the new relation. Thus, to map the M:N relationship between the entities 
MUTATION and REFRENCES, a new relation REFERSTO was created. RefID from 
REFRENCES and MutID from MUTATION were included as attributes of 
REFERS_TO. The primary key of REFERS_TO is a combination of the foreign keys 
MutID and RefID. The primary-cum-foreign keys, MutID and RefID, are depicted as 
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bold and underlined in Figure 2.3. The source of the foreign keys is indicated with 
arrows. 
Step 6: Mapping of Multi-valued Attributes. For each multi-valued attribute in the ER 
schema, a new relation was created. This relation included its own attribute plus the 
primary key of the entity of which the relation is an attribute. Thus, for the multi-valued 
attribute Dissev of MUTATION, a new relation DISEASESEV was created that 
contained the attribute Dissev and the primary key, MutID, of MUTATION. The 
primary key of DISEASESEV is a combination of Dis_sev and the foreign key MutID. 
The primary key is shown in bold and the foreign key is underlined in Figure 2.3. The 
source of the foreign key is indicated with arrows. The multi-valued attribute Dis_type 
was mapped in a similar mariner. 
Step 7: Mapping of N-ary Relationship Types. As there were no n-ary relationship 
types in the ER schema, this step was omitted. 
2.6 Population of the Database 
Manual Population. The first 70 records in the database were entered using batch files. 
A batch file is a text file containing a series of commands that can be executed in a 
sequence, one after the other, just as if they were typed in manually (Weddell, 2003). 
MySQL commands, to insert records into the database, were written into a text file and 
the text file was then executed. Each batch file inserted 10 records into the database. 
The database entries were verified against the paper-based records. 
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This method of data entry was used at the start because the front-end data entry 
form had not as yet been constructed. The use of batch files was also advantageous as it 
enabled the modification and fine-tuning of the database schema. Following changes to 
the schema, batch files allowed easy deletion and reentry of records. 
Automated Population. Once the mutation data entry form was constructed, as part of 
the front-end, mutations were entered one at a time using the browser-based form. 
Thirty-six mutations were entered in this manner. This method of data entry was also 
helpful in testing and de-bugging the underlying front-end code. The data entry form will 
be discussed in greater detail in Chapter 3. 
The next chapter describes the web pages that make up the front-end of the 
database, the software that was used to generate the pages, as well as the three tier 
architecture that was used to establish communication between the front-end and the 
database. 
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Chapter 3 Creation of the Database Front-end 
The front-end is that portion of software or a web site that is directly accessible to 
the end-user and is used to interact with or access other inaccessible parts of the software 
or web site. In this case, the database forms the back-end, while a web site forms the 
front-end. The web site, through web pages, allows the end-user to view the contents of 
the database, to enter data into the database and to query (request specific data from) the 
database. What access and how much access an end-user has to the database are 
determined by the web page designer. 
The creation of the database front-end involved installing the needed software, 
establishing a connection between the database and the front-end, and writing the scripts 
to generate the required web pages such as the mutation map, the mutation details page, 
the new mutation input form, and the mutation list query page. 
3.1 Software Used for Front-end 
XAMPP for Windows. The name XAMPP is an acronym for X (the X stands for the 
many operating systems it supports) Apache MySQL PHP Perl ("XAMPP," 2008). 
XAMPP is an installer that helps in the easy installation of Apache, PHP, and MySQL on 
a computer (McFarland, 2007). 
XAMPP was used as it is freely available. It is also very easy and fast to 
download and install (Seidler, 2007). It provides an Apache HTTP server and an 
interpreter for the PHP scripting language (McFarland, 2007), both of which were 
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required to generate dynamic pages. XAMPP also enables testing of front-end scripts 
without actually connecting to the internet (McFarland, 2007). 
Web Server - Apache 2.2. A web server is a program that accepts HTTP (hyper text 
transfer protocol) requests for web pages from a client (Brookshear, 2007). The client 
sending the HTTP request is a web-browser such as Internet Explorer, Mozilla Firefox, 
Safari or Opera. The request could be sent when, for instance, a user types a web address 
(URL) into the address bar of the browser or when a hyperlink is clicked on or a 
"Submit" button is pressed. The server responds with a web page (HTML document) 
which is then displayed by the browser (Brookshear, 2007). 
The content that is sent by the server is static if it comes from an existing file, 
such as a text file or HTML page (McFarland, 2007). However, the content is said to be 
dynamic if it comes from another program. Data that is pulled from a database by a 
program or script is considered dynamic (McFarland, 2007). 
Apache was used as it is one of the most popular HTTP servers on the World 
Wide Web (Pfaffenberger, 2003), is free, provides support for the server-side scripting 
language of choice PHP, and can be locally installed to test code during development. 
Server-side Scripting - PHP 5.1. Server-side scripting is used to generate dynamic 
HTML pages. A request sent to the web server, by the browser, is fulfilled by executing 
a script at the web server (Brookshear, 2007). Server-side scripting enables the user to 
access data stored in the database. It can also be used to validate data prior to its input 
into the database. 
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PHP is a widely used server-side scripting language (McFarland, 2007). PHP is a 
recursive acronym for PHP Hypertext Preprocessor (Pfaffenberger, 2003). PHP scripts 
can easily be embedded into any HTML document by simply surrounding the code with 
the delimiters <? and ?>. 
PHP was used because it is freely available, is easy to learn, and works well with 
the Apache web server and the MySQL database management system. 
Web Development Tool - Dreamweaver CS3. Adobe Dreamweaver is a web 
development tool. It is one of the most popular What-You-See-Is-What-You-Get 
(WYSIWG) editors (McFarland, 2007). A WYSIWG editor is especially helpful for 
those who have very little familiarity with web-development technologies. Dreamweaver 
automatically generates the HTML code required to create a web page. However, for 
those with some familiarity, it also provides a "code view" where the developer can 
access and modify the automatically generated code. 
Dreamweaver is suitable for generating dynamic web pages as, in addition to 
automatically generating HTML code, it can generate PHP and JavaScript (used for 
client-side scripting, explained in greater detail further in this section). It also provides 
support for Cascading Style Sheets (CSS), which is a language that allows a developer to 
specify how a web page will be presented; it allows the definition of style elements like 
color, font-size, font-style, and layout and thus helps in the separation of a document's 
content, given as HTML, from a document's style (Pfaffenberger, 2003). 
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The new version of Dreamweaver includes a Spry framework for Ajax, developed 
by Adobe. The Spry framework helps in the development of applications that use Ajax 
(McFarland, 2007). Ajax, an acronym for Asynchronous JavaScript and XML, is a 
collection of technologies that help in the creation of interactive web pages (Eichorn, 
2006). Dreamweaver's Spry framework allows the developer to create dynamic pages on 
the client-side; it allows the inclusion of animation effects, stylized menus and tabbed 
panels, and form validation. 
Client-side Scripting - JavaScript Client-side scripting refers to programs that are 
executed by the web browser as opposed to the web server. It allows the creation of 
dynamic HTML pages where the content of the page doesn't remain fixed but changes 
depending on the web site user's input (Brookshear, 2007). 
JavaScript is one of the languages used to write client-side scripts. The code can 
either be embedded in an HTML document or it can be included from a separate file. 
JavaScript can be used to open popup windows with messages, to disable or enable the 
elements in an input form based on user input, to validate form input, and to detect user 
actions like clicking a mouse button or moving the cursor over a link or image. As 
JavaScript is run by the browser, it can respond faster to user actions and hence can give 
the web page an interactive feel (McFarland, 2007). However, JavaScript will only work 
if the user's browser supports this scripting language and has it enabled. 
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3.2 Establishing a Connection between the Database and the Front-end 
In order to establish a connection between the database and the front-end, a 
private network was set up between the host machine and the guest virtual machine (both 
set up on the same computer). Dreamweaver was used to help connect to the database. 
Host Machine 
Windows XP 
m i 
JavaScript 
Virtual Machine 
Linux 
MySQL 
DB 
Figure 3.1. Three-tier architecture. The web browser forms the first tier, the 
application server forms the second tier, while the database server forms the third 
tier. 
As described in Chapter 2, for development and testing purposes, the MySQL 
database was located on the virtual machine, while the Apache web server and PHP were 
located on the host machine. The guest operating system was Linux, while the host 
operating system was Windows XP. Mozilla Firefox and Internet Explorer were used for 
testing code. The PHP script is executed by the Apache web server, while JavaScript is 
executed by the web browser being used. The three-tier setup can be seen in Figure 3.1. 
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3.3 The Mutation Map 
Obtaining the Sequence of the Beta Globin Gene. The sequence for the beta globin 
gene was obtained from the book by Weatherall and Clegg (2001). The BLAST (Basic 
Local Alignment and Search Tool) program, provided online by NCBI (National Center 
for Biotechnology Information), allows comparison of sequences, to check for sequence 
similarity. Nucleotide blast, also called blastn, was used to compare the sequence 
obtained from Weatherall and Clegg with all the human genomic sequences in the NCBI 
database. The sequence provided by the book and that stored by the NCBI database 
were found to be completely identical. 
Design of the Mutation Map. The idea of a mutation map is credited to Dr. Sami Khuri, 
Professor (and thesis committee member for this project), Department of Computer 
Science, San Jose State University. The original mutation map was designed by Dr. 
Khuri and Keith Callenberg (2007), an undergraduate Computer Science major at San 
Jose State University. 
The mutation map created for this project is shown in Figure 3.2. It extends from 
nucleotide -120 to +1706 of the beta globin gene. Nucleotides -120 to -1 are shown in 
lower case and represent the promoter of the gene. The important regulatory elements in 
the promoter, such as the two CACCC boxes, the CCAAT box, and the TATA box, are 
depicted in red. These regulatory elements are required for the optimal binding of 
transcription factors and the efficient initiation of transcription (Basran, Reiss, & Luo, 
2008). 
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The transcribed portion of the beta globin gene is 1606 bases long and is shown in 
upper case letters. The gene has three exons and two introns. Nucleotides +1 to +50, 
shown in black, represent the 5'UTR (untranslated region), which forms part of exon 1. 
Nucleotide regions shown in blue represent the open reading frame of the gene. The 
three nucleotides forming each codon are grouped together. The open reading frame 
begins at the start codon (ATG) at position +51, in exon 1, and ends at the stop codon 
(TAA) at position +1472, in exon 3. The two introns, also called intervening sequences 
(IVS), are shown in black. Nucleotides +1475 to +1606, shown in black, represent the 
3'UTR (untranslated region), which forms part of exon 3. The 3'UTR contains the 
polyadenylation signal sequence (AATAAA), depicted in red, that signals the 3'cleavage 
of the primary mRNA transcript. The 3'flanking region of the gene, extending from 
nucleotide +1607 to +1706, is shown in lower case. The overall structure of the beta 
globin gene can be seen in Figure 3.3. 
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Mutation Map 
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T G T G T T C A C T A G C A A C C T C A 
A A C A G A C A C C ATG GTG CAT CTG ACT 
CCT GAG GAG AAG TCT GCC GTT ACT GCC CTG 
TGG GGC AAG GTG AAC GTG GAT GAA GTT GGT 
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A G G CTG CTG GTG GTC TAC CCT TGG ACC 
CAG AGG TTC TTT GAG TCC TTT GGG GAT CTG 
TCC ACT CCT GAT GCT GTT ATG GGC AAC CCT 
AAG GTG AAG GCT CAT GGC AAG AAA GTG CTC 
GGT GCC TTT AGT GAT GGC CTG GCT CAC CTG 
GAC AAC CTC AAG GGC ACC TTT GCC ACA CTG 
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T T 
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A T T A C T A T T T G G A A T A T A 
T G T G C T T A T T T G C A T A T T 
T A A T C T C C C T A C T T T A T T 
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A T A A T C A T T A T A C A T A T T 
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G T 
T T 
C T 
A C 
A G 
CTG 
CCA 
GTG 
AAG 
G C 
G G 
C C 
T A 
A T 
C A T A T A A A T A T T T C T G C A 
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CTC CTG GGC AAC GTG CTG GTC TGT GTG 
GCC CAT CAC TTT GGC AAA GAA TTC ACC 
CCA GTG CAG GCT GCC TAT CAG AAA GTG 
GCT GGT GTG GCT AAT GCC CTG GCC CAC 
TAT CAC TAA G C T C G C T T T C T T 
T G T C C A A T T T C T A T T A A A 
T T C C T T T G T T C C C T A A G T 
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Figure 3.2. The mutation map (split into two columns). 
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5'UTR introns 3'UTR 
Exonl Exon2 Exon3 
Figure 3.3 The structure of the beta globin gene. (UTR-Untranslated region) 
As the cursor is moved over different bases, a hand tooltip pops up to give more 
information about the related map position. The tooltip can be seen in Figure 3.4. The 
tooltip includes information such as the position of the base, relative to the start point of 
transcription, and the structural location of the base. If the base is part of a codon, the 
codon number and the amino acid encoded by the codon are included in the tooltip. If the 
base is part of an intron, the position of the base, relative to the 5' exon-intron junction, is 
given. 
AAG GIG AAG GCT CAT GGC AAG AAA GTG CTC 
GGT GCC TTT AGT GA^^GGC CTG GCT CAC CTG 
GAC AAC CTC AAG G(^^^^^^S GCC ACA CTG 
AGT GAG CTG CAC TGT GAC AAG CTG CAC GTG 
Figure 3.4. A customized tooltip. On the map page the tooltip provides detailed 
information about every map position. 
Base positions that have one or more mutations associated with them are 
underlined. These underlined bases are hyperlinks that can be clicked on to open a 
mutation details page (described in Section 3.4). The details page contains the 
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information about the associated mutations. Base positions that have no attached 
mutations are not underlined. Clicking on such bases produces a popup box that informs 
the user that the position has no mutations recorded. 
When mutations, related to a new position, are added to the database, the 
corresponding base position is automatically underlined in the mutation map when the 
web page reloads. 
Underlying Code for the Mutation Map. The background code that generates the 
mutation map contains a series of anchor tags, each of which references the file that 
contains the code for generating the mutation details page. The map position of each 
base is passed to the program file so that only mutation details related to that particular 
map position will be displayed. 
A combination of PHP and JavaScript were used to produce both the automated 
underlining of links and the popup box, generated for map positions that have no 
associated records. The code has been included in Appendix A. The pseudocode is 
given below: 
establish a connection with the database 
declare an array 
for each map position 
determine if there are corresponding mutations (records) in the database 
if records are found 
assign the map position to the array 
else 
if map position is clicked on 
show a popup box with "no records" message 
endif 
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endif 
endfor 
if page loads 
for each map position in the array 
underline the corresponding map position 
endfor 
endif 
3.4 The Mutation Details Page 
Design of the Mutation Details Page. The mutation details page contains all the 
information pertaining to the mutations that were found associated with a particular map 
position. A sample page, for the +140 map position, is shown in Figure 3.5. Currently, 
in the database, map positions have between 0-3 mutations associated with them. 
The titles of the references (seen underlined in Figure 3.5) are hyperlinks. 
Clicking on the title opens up the PubMed page with the abstract for the related journal 
article. Hovering over the hyperlink shows a tooltip with the PubMed identification 
number (PMID) of the article. 
Underlying Code for the Mutation Details Page. Primarily PHP and HTML were used. 
The high-level code is given below: 
establish a connection with the database 
select all records from all tables where mutation position = map position passed by 
hyperlink (on clicking) 
if records are not found 
display a message saying no records found 
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else 
endif 
for each record found 
appropriately format and display the record 
endfor 
Mutation Data 
, _ _ 
Mutation ID: 
1 Mutation Description: 
I 
I Mutation Tvpe: 
Starting Position of 
Mutation: 
Mutation Length: 
Mutation Location: 
Mutation Affects: 
I Thalassemia Type: 
Thalassemia Severity: 
Population Found in: 
Comments: 
References: 
Record Added Last 
Updated By: 
80 
Codon 29(GGC->GGT) 
Substitution - Transition. Silent 
140 
1 
Exon 1 - Codon 29 
mRNA processing - Creates cryptic splice site in exon 
beta-
Unknown 
Lebanese (Rare mutation) 
Mutation can also be referred to as IVS-I(-3)(C->T), Change in 
amino acid code Gly->Glv. The substitution occurs 2 nucleotides 
upstream of the GT splice donor site creating a new, competing. 
splice donor site (Normal splicing - GGC AGjGTTGGT -> 
Abnormal splicing - GiGTAGGTTGGT). As some normal splicing 
of the mRNA still occurs the mutation results in beta4- thalassemia. 
• Chehab FF. Der Kaloustian V. Khouri FP, et al. The molecular 
basis of beta-thalassernia in Lebanon: application to prenatal 
diagnosis. Blood. Apr 1987; 69(4): 1141-5. 
Shaluon February 2], 200S at 11:00:50 am 
Figure 3.5. The mutation details page. 
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3.5 The New Mutation Input Form 
Design of the New Mutation Input Form. The mutation input form allows the curator of 
the database to add new mutation records to the database. The input form can be seen in 
Figure 3.6. 
Mutation ID: 
Mutation Description: 
Mutation Type: 
Starting Position: 
Mutation Length: 
Mutation Location: 
Mutation Effect: 
Disease Type: 
Disease Severity: 
Comments: 
107 
[Example: -56(G->C; 
|Enter new Mutation Type here 
-Choose one--
~3 
Eg -56 
Eg:1 
Example: Promoter 
Enter new Mutation Effect here, 
C beta* (silent) 
(f beta* 
<~ betaO 
<~ beta(0 or + unclear) 
r Thalassemia Major 
f Thalassemia Intermedia 
F" Thalassemia Minor 
P Unknown 
Distribution: A*f'W ) Delete row | 
References: Add row | Delete row 
-3 
"3 
Insert record j Reset form 
Figure 3.6. The new mutation input form. 
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The Mutation ID is automatically generated. An example is provided on how to 
enter the Mutation Description. An existing Mutation Type can either be chosen from a 
drop-down box or a new Mutation Type can be entered into a text box. If a Mutation 
Type is selected from the drop-down box, the text box is disabled, and vice-versa, to 
ensure that just one Mutation Type is entered for a mutation. The selection list of the 
drop-down box is drawn from the existing values in the database. The Starting Position of 
the mutation refers to the map position of the first base that is mutated. In case of an 
insertion, the base position of the first base in the insertion is taken as the Starting 
Position. For instance, if a base C is inserted between an A (position +40) and a T 
(position +41), the inserted base C is now at position +41 and hence +41 is taken as the 
Starting Position of the insertion. 
The Mutation Length specifies the number of bases involved in the mutation. 
Examples for the Starting Position and Mutation Length are included in their respective 
text boxes. Clicking inside the text box removes the example, thus emptying the text box 
for data entry. An example is provided, in a similar manner, for Mutation Location. 
Mutation Effect is dealt with much like Mutation Type where both a drop-down box, for 
existing values, and a text box for the entry of new values is provided. Just one Mutation 
Effect, an existing one or a new one, can be added. Radio buttons are provided for 
Disease Type where only one selection can be made. On the other hand checkboxes are 
provided for Disease Severity where multiple choices can be made. The same mutation 
can result in different disease severities depending on whether the individual has just one 
mutated allele, has two mutated alleles, or has other modifying factors present. If the 
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Unknown option is selected for Disease Severity the other options are disabled and vice-
versa. 
The Comments text area has a character counter on the side which can be seen in 
Figure 3.7. If the character count exceeds the limit, an error message is displayed. 
Dreamweaver's Spry framework was used to add the character counter. 
Comments: Wo raRKA was found. 
18 
Figure 3.7. The Comments text area with a character counter (seen on the 
bottom right). 
The Distribution includes the Nationality, Ethnicity, and Frequency. The 
Nationality can be selected from a drop-down box of existing nationalities or a new 
nationality can be entered into the provided text box. The Ethnicity can be typed into a 
text box. The Frequency can be selected from one of 4 fixed values - Common, Rare, 
Novel, and Unknown. As a single mutation can be found in multiple populations, an Add 
Row button is provided to enable the addition of multiple distributions. The Delete Row 
button can be used to delete an unwanted row or record. 
The References were handled in a similar manner where Add Row and Delete 
Row buttons were provided to enable the addition of multiple records. Each reference 
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has a Reference ID that is automatically generated. Text boxes are provided for the 
PubMed ID (PMID), the names of the first three authors, the title of the article, the 
volume number, the issue number, the year of publication, and the page numbers. Drop-
down boxes are provided for the name of the journal and the month of publication. 
While the Month drop-down box contains a fixed set of values, the Journal drop-down 
box contains a selection list based on the existing journal names in the database. A 
check-box is provided to indicate whether the article has more than 3 authors. The page 
numbers can be entered by the curator as abbreviated numbers (301-10) or as complete 
numbers (301-310). If the pages are entered as complete numbers, the underlying code 
converts the numbers to the abbreviated format that is used in reference citations. 
Finally, two buttons are available at the bottom of the page, the Insert Record 
button allows the entered values to be submitted to the database, while the Clear Form 
button resets all the fields enabling values to be re-entered. 
The contents of a field are checked dynamically and errors messages are 
generated, without refreshing the page, using Dreamweaver's Spry framework. Sample 
error messages can be seen in Figure 3.8. 
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Starting Position: f£66' The map begins at -120. 
Mutation Length: JEgii A value is required. 
Figure 3.8. Dynamically generated error messages. The first message 
prompts the user to enter a valid value for the starting position while the second 
message warns the user about a blank field. 
Underlying Code for the New Mutation Input Form. HTML form elements were used 
to create the page. In addition, a combination of PHP, JavaScript, and Dreamweaver's 
Spry framework was used to make the page dynamic. PHP was used to populate the 
drop-down boxes with existing database values and to insert the entered values into the 
appropriate tables and columns. The curator name and the date and time of record entry 
are automatically added to the database using PHP. PHP was also used to abbreviate the 
page numbers prior to entry into the database. On the other hand, JavaScript was used to 
disable or enable form elements, based on changes made by the user. JavaScript was also 
used to reset the form, and to add and delete rows to tables. Dreamweaver was used for 
form validation and for generating error messages. 
3.6 The Mutation List 
Design of the Mutation List Query Page. The query page allows database users to 
generate mutation lists. The users can either choose to look at a list of all the mutations 
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in the database or they can create a mutation list that is filtered based on various user 
defined criteria. The query page can be seen in Figure 3.9. 
Mutation List - Query Page 
<~ Show imfiltered mutation list 
<~ Show filtered mutation list 
Filter by Nationality-: |-Choose one- 3 
Filter by Mutation Frequency: J—Choose one—_J 
Filter by Ethnicity: | —Choose one— 2I 
Filter by Disease Type: |—Choose one— J 
Filter by Disease Severity: j -Choose one- 3 
Submit 
Figure 3.9. The mutation list query page. This page allows web site users to 
create filtered or unfiltered mutation lists. 
The web site user can filter the mutations based on Nationality. The drop-down 
box provides a list of the nationalities currently available in the database. The user can 
also filter the mutation list by disease severity, disease type, and mutation frequency. 
Some of the ethnicities that frequently occur in the database are provided in the Ethnicity 
drop-down box. The list of ethnicities is a static list and can be seen in Figure 3.10. 
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Filter by Ethnicity: [ —Choose one— Irl 
Filter by Disease T>| 
Filter by Disease Se 
Submit I 
Black 
Chinese 
Greek 
Italian 
Jew 
Maharashtrian 
Muslim 
Punjabi 
Southern Chinese 
Southern Italian 
H 
U 
Figure 3.10. Options available for filtering mutations by ethnicity. 
Underlying Code for the Mutation List Query Page. HTML form elements were used to 
create the page. PHP was used to generate the dynamic list for the Filter by Nationality 
drop-down box. 
Design of the Mutation List Page. The list page displays a filtered or unfiltered list of 
records from the database. The list page can be seen in Figure 3.11. The number of 
mutations and associated references found is displayed above each table. The only fields 
excluded from the mutation list are Comments and Updation Date and Time. The 
reference titles, as in the mutation details page, link to the article abstract in PubMed. 
The Reference ID, which was omitted from the details page, can be seen here. 
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Mutation List 
1 Riutation(s) fount I. 
Mut. ,. . . ,,. Startine ,, _,.,- , Disease Disease _. ., Entered 
IT., Description Jvpe „ . . *- Length Location tnect ,_ r. Distnbution ID Position Ivpe Seventy Bv 
81 IVS-L 3' 
end; -17bp Deletion 256 17 
Intron 1 
Position 
+114 to 
+130 
mRNA 
processing 
Abolishes 
splicing at 
3' splice 
site 
betaO Unknown Kuwaiti Shalu 
Reference List 
1 refexence(s) found. 
106 3048433 
Cazazian 
HH Jr. 
3oehm CD 
Molecular basis and prenatal 
diagnosis of beta-thalassemia. Blood 
7T 4 Oct 1988 1107-16 
Figure 3.11. A sample mutation list. This list is generated when the option 
Filter by Nationality: Kuwaiti is chosen. 
Underlying Code for the Mutation List Page. When the user clicks on the Submit button 
of the query page, the user's selections are passed, as variables, to the file containing the 
code for generating the list page. PHP and HTML elements were used to generate the list 
page. Based on the user's choice of filter, a query is constructed. PHP is then used to 
connect to the database and obtain the relevant records from the database. HTML is used 
to generate the table of records. 
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The following chapter provides some statistics based on records currently in the 
database. It also enlists some conclusions that could be made by examining the database 
contents. 
46 
Chapter 4 The Database Content 
As of now, the database contains 106 mutations. These mutations are located in 
the promoter, the 5' and 3' UTRs, the open reading frame and the first intron. A listing 
of all 106 mutations can be seen in Appendix B. Given below are some statistics based 
on the records in the database: 
Mutation Locations 
• Twenty-eight of the mutations are located in the promoter of the gene. Nearly 
all of these mutations are found in the regulatory elements. Most of the 
promoter mutations are found in the TATA box, followed by the proximal 
CACCC box. Fewer mutations are based in the CCAAT box and the distal 
CACCC box. 
• Eight of the mutations are located in the 5'UTR, while nine mutations fall in 
the 3'UTR. Most of the 3'UTR mutations are located in the polyadenylation 
signal sequence, AATAAA. 
• Most of the open reading frame mutations are found in Exon 1 (40 of a total of 
55 exonic mutations). 
• Nine mutations are based in Intron 1. The majority of these mutations affect 
the intronic 5' and 3' splice consensus sequences. 
• Most base positions have one or two mutations associated with them, 
however, bases -87, +52, +53, and +144 have three attached mutations each. 
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-87 is part of the proximal CACCC box, +52 and +53 are part of the start 
codon (ATG), while +144 is part of the important GT dinucleotide of the 
intron 1-5' splice consensus sequence. 
Mutation Effects 
• The processes most often affected by the mutations are transcription followed 
by mRNA translation. 
Mutation Types 
• Substitutions are the most frequently seen type of mutations (68 of 106) 
amongst which transversions are slightly more common than transitions. 
Deletions (30) are seen far more often than insertions (8). 
• The longest mutation in the database is a 105 base pair deletion, extending 
from base positions -25 to +80. However, overall, there are fewer insertions 
or deletions involving more than two bases. Large deletions, that involve 
more than the beta globin gene, have been excluded from the database. 
Mutation References 
• Almost all the 106 mutations in the database, with the exception of 4, have 
curator comments attached that are drawn from the references. 
• The mutations reference some 139 different sources. 
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• The largest number of references are drawn from the journal Hemoglobin 
followed by the British Journal of Haematology. 
• The oldest article in the database is from June 1979, while the latest article 
referenced is from February 2008. 
• Two of the mutations have six associated references. The article that is 
referenced the most (six times) by various records is beta-thalassemia 
mutations in Japanese and Koreans (Ohba, Hattori, Harano, Harano, 
Fukumaki, & Ideguchi, 1997). 
Disease Types 
• Most of the mutations result in a disease type of betaO (56 of 106). 
Disease Distribution 
• The database includes 46 nationalities and 45 different ethnicities. 
• The nationality with the most associated mutations are Asian Indians (13 
mutations), followed by Turks (12). 
• The ethnicities that have the most mutations in the database are US-Blacks 
(10), followed by Asian Indian - Punjabis (4). Ashkenazi, Sephardic, and 
Kurdish Jews (belonging to different countries like Iran, Israel, Russia, and 
Canada) have 6 associated mutations in the database. 
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• Twelve of the mutations have a high frequency (are common mutations) in the 
population in which they are found. The remaining are rare (28) or novel (46) 
or have an unknown frequency (42). 
Most of the above statistics are reflective of what one would expect to find with 
beta thalassemia mutations. For instance, most beta thalassemia mutations are known to 
be substitutions (Giardine et al, 2007), a few common mutations are found in each 
population while the majority of mutations are rare or novel (Weatherall, 2004). 
By studying and comparing the properties of the various mutations in the 
database, some interesting conclusions can be drawn. Furthermore, information can be 
obtained about the disease and its variations by looking at the given curator comments. 
Some examples of what one could learn about thalassemia, by examining the database 
contents, are given below: 
Patient Genotype 
• Most severely affected patients of beta thalassemia are compound 
heterozygotes for two beta thalassemia alleles or a beta thalassemia allele and 
a hemoglobin variant. Hemoglobin variants are beta globin mutations that 
affect the quality of hemoglobin as opposed to the quantity. 
• Homozygous beta thalassemia results from consanguineous marriages, that is, 
marriages between relatives such as first-cousins. This is seen amongst the 
Jewish Kurds, who are a highly in-bred ethnic group. 
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Beta Thalassemia in Different Populations 
• Black patients, from the US, tend to have a milder form of thalassemia. The 
mutations they carry usually lead to beta+ thalassemia and thalassemia 
intermedia. Black patients, also, often have a thalassemia mutation associated 
with HbS, the sickle-cell anemia causing hemoglobin variant. 
• Patients from Northern Africa (Algeria and Tunisia) also show compound 
heterozygosity with HbS. 
• Most Thai patients carry a thalassemia mutation combined with the 
hemoglobin variant HbE. 
• The island of Corsica is the only place in France where beta thalassemia is 
endemic. 
• A promoter mutation (-29 (A->G)) is the most common mutation found in 
both US-Blacks and Chinese. However, the same mutation may have likely 
arisen independently in the two populations as no major interactions, between 
the two populations, have occurred. 
• Mutations found in New World patients (US, Canada, Mexico, Surinam) and 
Northern European patients are seen as a result of immigration from regions 
where thalassemia has been prevalent such as Africa, Southern Europe, the 
Middle-east, and India. A few mutations in these regions are the result of 
novel mutations. 
• Beta thalassemia is a severe disorder amongst Bulgarians and Sardinians. On 
the island of Sardinia beta thalassemia arose as a single mutational event. 
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Disease Type and Severity 
• Most of the promoter and UTR mutations tend to result in a milder disease, as 
they cause only beta+ or silent beta+ thalassemia. Silent beta thalassemia is a 
very mild form of beta thalassemia; patients heterozygous for such mutations 
are hematologically normal and the condition is only detected when combined 
with another more severe beta thalassemia mutation. Promoter and UTR 
mutations frequently result in thalassemia intermedia. 
• Exonic mutations usually affect the open reading frame and hence result in 
betaO thalassemia and thalassemia major. The mRNA transcript carrying a 
frame-shift mutation is generally destroyed prior to translation. 
• Intronic mutations result in betaO thalassemia and thalassemia major as they 
tend to affect splicing. The improperly spliced mRNA transcripts are 
destroyed prior to translation. 
Mutation Locations 
• The majority of the disease-causing promoter mutations are located in the 
regulatory elements of the promoter, as these regions are important for the 
binding of transcription factors and the efficient initiation of transcription. 
The distal CACCC box has fewer mutations than the proximal CACCC box, 
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although the same factors bind to both, suggesting that the proximal box plays 
a more important role in transcription initiation. 
• When a region or a base does not have mutations associated with it, it just 
means that no patients have been found carrying a mutation at that position or 
within that region, most likely because the mutation has little or no effect on 
the individual. There is also a small likelihood that the region in question is 
somewhat less prone to mutations, for instance, due to the presence of fewer 
repeats. As such, overall, the beta globin gene is considered a hot-spot for 
mutations (Das & Talukder, 2001). 
Mutation Effects 
• Silent mutations, that do not change the amino acid encoded by a codon, may 
not seem to affect the polypeptide sequence, but may actually cause disease 
by disrupting a splice site. 
• Some seemingly harmless mutations in the exons or introns may give rise to 
cryptic splice sites which may compete with the actual splice sites. 
• The destruction of a splice site due to a mutation may at times give rise to 
multiple cryptic splice sites that are then utilized as alternatives. 
• Some mutations create or disrupt the recognition site for a restriction enzyme. 
This fact may help in the identification of a mutation. 
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Disease Variants 
• If a beta thalassemia mutation is simultaneously inherited with an alpha 
thalassemia, the carrier of the mutations may have a milder disease or may be 
totally asymptomatic. The presence of both types of thalassemias helps 
reduce the imbalance between the alpha and globin chains thus reducing 
disease severity. 
• If a beta thalassemia mutation is simultaneously inherited with a mutation in 
the gamma globin gene, a less severe form of beta thalassemia is seen. The 
gamma globin gene encodes gamma globin, a component of the fetal 
hemoglobin, HbF. Certain mutations in the gamma globin gene cause fetal 
hemoglobin to persist into adulthood, a condition referred to as the Hereditary 
Persistence of Fetal Hemoglobin (HPFH). Patients that simultaneously inherit 
beta thalassemia and HPFH usually suffer from thalassemia intermedia 
instead of major. 
• Promoter mutations in the beta globin gene sometimes lead to an indirect 
increase in the production of delta globin, a component of the minor adult 
hemoglobin HbA2. As beta and delta globin have a close evolutionary 
relationship, the similar promoter regulatory elements in the delta globin gene 
may compete for the common transcription factors. An increase in delta 
globin production leads to a less severe disease and likely results in 
thalassemia intermedia. 
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• The insertion of a codon may give rise to a dominant betaO thalassemia. The 
abnormal mRNA is translated into a beta chain with an extra amino acid 
which does not bind to the alpha-chain, resulting in dominant betaO 
thalassemia. This condition results in the destruction of beta chains and an 
accumulation of alpha chains. 
Mutation Types 
• Beta thalassemia is mostly caused by substitutions. Also, substitutions 
involving transversions are more likely to cause disease than those involving 
transitions. This can be explained by the fact that transversions involve a 
dramatic change in chemical structure. 
• Most disease causing insertions and deletions are those that lead to 
frameshifts. This is expected as frameshifts would majorly alter the open 
reading frame of the gene. 
• Most insertions and deletions are found in regions of short repeats. The 
repeats could lead to slipped strand mispairing, during DNA replication, 
which would in turn result in an insertion or deletion. 
The following chapter puts forward some ideas for the further enhancement of the 
created database. 
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Chapter 5 Plans for Future Improvements 
Given below are some of the suggestions for improvement of the Beta 
Thalassemia Database: 
• Input Form 
o Users can be provided with a guide on how to enter a mutation using 
the form. 
o The functionality of the form can be improved. For instance, along 
with the delete row option the users can be allowed to choose the row 
to be deleted (as of now only the last row can be deleted). 
o More Ajax driven error checks can be added to the form. 
• Mutation List 
o The user can be allowed to choose which columns are to be included 
in the mutation list, 
o A filter allowing display of mutations by continent or world region 
could be added, 
o More complex compound queries, combining two or more filters can 
be added. For example, users could be allowed to filter mutations by 
nationality and disease severity. 
• Overall Improvements 
o More mutations could be added. 
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o Users could be allowed to login, leave comments for a mutation or 
leave suggestions. A user forum could also be provided, 
o Thalassemia information and resources for patients could be included, 
o Links to the latest thalassemia news could be provided, 
o Information could be provided to students about 
• the functions of various parts of a gene, 
• mutation nomenclature, 
• the causes of different types of mutations, 
• the effects of different mutations, 
• the inheritance of thalassemia, 
• the relation between malaria and thalassemia, 
• thalassemia treatment and prevention, 
• the spread of thalassemia mutations within populations, 
• haplotypes and their use in the study of thalassemia mutations, 
• restriction enzymes and their use in detecting mutations, 
• information about beta thalassemia variants (e.g., thalassemia 
intermedia, silent beta+ thalassemia, dominant betaO 
thalassemia), 
• the structure of hemoglobin, 
• processes involved in the formation of hemoglobin from the 
gene, 
• the different types of globins, and 
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• the evolution of the globins. 
o Disease related information specific to a nationality or ethnicity could 
be given. Measures adopted by certain countries, like Cyprus, to 
successfully reduce beta thalassemia rates could also be included. 
o Authentication for the curator should be provided. 
These improvements, if implemented, will make the web site easier to use as well 
as more comprehensive and informative. 
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Appendix A 
Code for Automated Underlining of Hyperlinks 
The following code detects which map positions in the mutation map have 
associated mutations in the database and then proceeds to underline those map positions. 
Underlining indicates that the map position is a hyperlink that can be clicked on to 
display the details of the associated mutations. This piece of code overcomes the 
problem of having to manually convert map positions into hyperlinks every time the 
database is updated and mutations are added to new positions. 
<?php 
require_once('Connections/conn2ThalassemiaDB.php'); 
//Declaring a PHP array. 
$Und_pos_arr= array(); 
//For each map position, connecting to the database and determining if there are mutation 
records associated with the position. 
for ($Map_pos=-120; $Mapjpos <=+1706; $Map_pos++) 
{ 
mysql_select_db($database_conn2ThalassemiaDB, $conn2ThalassemiaDB); 
$query_Recordsetl = sprintf ("SELECT MUTATION.MutID FROM MUTATION 
WHERE Strt_pos = %s", $Map_pos); 
$Recordsetl =mysql_query($query_Recordsetl, $conn2ThalassemiaDB) or 
die(mysql_error()); 
$row_Recordsetl = mysql_fetch_assoc($Recordsetl); 
$num_rows=mysql_num_rows($Recordsetl); 
//If mutations are found associated with a position, the map position is assigned to the 
declared PHP array. 
//If no associated mutations are found, when a user clicks on the map position, a popup 
box is displayed. 
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if ($num_rows > 0) 
{ 
$Und_pos_arr[]=$Map_pos; 
} 
else 
{?> 
<script type="text/javascript"> 
<!--
var Norecs = document.getElementById(<?php echo $Mapjpos ?>); 
No_recs.onclick= function showBox() 
{ 
alert ("Sorry, no mutations recorded for this position."); 
return false; 
} 
--> 
</script> 
<?php 
} 
} 
?> 
<!~When the page reloads, each map position stored in the PHP array is underlined~> 
<script type="text/javascript"> 
<!--
window.onload= function Changes() 
{ 
<?php foreach ($Und_pos_arr as $Und_pos) 
{?> 
document.getElementById(<?php echo $Undjpos ?>).style.textDecoration="underline"; 
<?php 
}?> 
} 
—> 
</script> 
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